Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (GLOBOSTAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03992417
Recruitment Status : Active, not recruiting
First Posted : June 20, 2019
Last Update Posted : May 9, 2022
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Sanofi

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Primary Objective:

To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD

Secondary Objectives:

  • To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching)
  • To assess the long-term effectiveness of Dupixent® in AD patients in a real-world setting
  • To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in patients who receive Dupixent® for AD
  • To collect safety data on study participants

Condition or disease Intervention/treatment
Dermatitis Atopic Drug: Dupilumab SAR231893 (REGN668)

Detailed Description:
Participants enrolled in the study will be followed for 5 years.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 897 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 60 Months
Official Title: A Prospective Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis
Actual Study Start Date : June 11, 2019
Estimated Primary Completion Date : March 31, 2027
Estimated Study Completion Date : March 31, 2027

Resource links provided by the National Library of Medicine

Drug Information available for: Dupilumab

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Participants with AD
Adult and adolescent participants with AD initiating treatment with Dupixent® for AD according to the country-specific prescribing information, as part of their usual care as determined by their physician
 Drug: Dupilumab SAR231893 (REGN668)

Pharmaceutical form: solution for injection

Route of administration: subcutaneous injection

Other Name: Dupixent®


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Baseline Characteristics: Medical history [ Time Frame: Baseline to Month 60 ]
  2. Baseline Characteristics: Socio-demographics [ Time Frame: Baseline to Month 60 ]
  3. Baseline Characteristics: Disease characteristics [ Time Frame: Baseline to Month 60 ]

Secondary Outcome Measures :
  1. Physician Assessment: Body Surface Area Affected (BSA) by Atopic Dermatitis [ Time Frame: Baseline to Month 60 ]
    Percentage of BSA affected by AD assessed for each major section of the body

  2. Physician Assessment: Eczema Area and Severity Index (EASI) [ Time Frame: Baseline to Month 60 ]
    Measure used in clinical practice and clinical trials to assess the severity and extent of AD

  3. Physician Assessment: Scoring of Atopic Dermatitis (SCORAD) [ Time Frame: Baseline to Month 60 ]
    Measure used in clinical practice and clinical trials to standardize the evaluation of the severity and extent of AD

  4. Participant Assessment: Patient Oriented Eczema Measure (POEM) [ Time Frame: Baseline to Month 60 ]
    Questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults

  5. Participant Assessment: Pruritus Numerical Rating Scale (NRS) [ Time Frame: Baseline to Month 60 ]
    Individual NRS used to rate the intensity of pruritus using a 0 to 10 numeric rating scale

  6. Participant Assessment: Skin Pain or Soreness NRS [ Time Frame: Baseline to Month 60 ]
    Individual NRS used to rate skin pain and soreness using a 0 to 10 NRS

  7. Participant Assessment: Skin Feeling Hot NRS [ Time Frame: Baseline to Month 60 ]
    Individual NRS used to rate the sensation of skin feeling hot (burning sensation) using a 0 to 10 NRS

  8. Participant Assessment: Skin Sensitivity NRS [ Time Frame: Baseline to Month 60 ]
    Individual NRS used to rate skin sensitivity using a 0 to 10 NRS

  9. Participant Assessment: Sleep Disturbance NRS [ Time Frame: Baseline to Month 60 ]
    Individual NRS used to report the severity of their sleep disturbance using a 0 to 10 NRS

  10. Participant Assessment: Dermatology Life Quality Index (DLQI) for adults and Children Dermatology Life Quality Index (CDLQI) for adolescents [ Time Frame: Baseline to Month 60 ]
    Questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL)

  11. Participant Assessment: Juniper Asthma Control Questionnaire (ACQ-5) [ Time Frame: Baseline to Month 60 ]
    Questionnaire to evaluate asthma control in participants with comorbid asthma

  12. Participant Assessment: Allergic Rhinitis-Visual Analog Scale (AR-VAS) [ Time Frame: Baseline to Month 60 ]
    Instrument for the documentation of symptoms and therapy monitoring in allergic rhinitis

  13. Participant Assessment: Work Productivity and Activity Impairment Questionnaire for AD (WPAI-AD) for adults and Work Productivity and Activity Impairment Questionnaire+Classroom Impairment Questions for AD (WPAI-CIQ-AD) for adolescents [ Time Frame: Baseline to Month 60 ]
    Questionnaire to assess the impact of AD on productivity

  14. Participant Assessment: Health Care Resource Utilization Questionnaire [ Time Frame: Baseline to Month 60 ]
    Questionnaire regarding hospitalization, or emergency room/urgent care center visits due to AD

  15. Participant Assessment: 9-Item Treatment Satisfaction Questionnaire for Medication (TSQM-9) [ Time Frame: Baseline to Month 60 ]
    Instrument to measure treatment satisfaction

  16. Adverse events (AEs) [ Time Frame: Baseline to Month 60 ]
    Number of participants with at least 1 AE

  17. Participant Assessment: Atopic Dermatitis Control Tool (ADCT) to be collected optionally [ Time Frame: Baseline to Month 60 ]
    Questionnaire related with Atopic dermatitis control


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The target population is adult and adolescent patients (male or female, ≥12 years old), who are initiating treatment with Dupixent® for AD according to the country-specific prescribing information.
Criteria

Inclusion Criteria:

  • Male or female, 12 years or older at the baseline visit. Note: Adolescent participants (at least 12 years old, but less than 18 years) are eligible only after Dupixent® receives the respective country's regulatory approval for use in this age group;
  • Initiating treatment with Dupixent® for AD according to the country-specific prescribing information. Note: Participants may be eligible if they have already initiated treatment with Dupixent® for AD within 6 months before their enrollment in the registry, provided that all core baseline data required (Eczema Area and Severity Index [EASI], Scoring of Atopic Dermatitis [SCORAD], body surface area [of AD involvement] [BSA], Patient-Oriented Eczema Measure [POEM], and Dermatology Life Quality Index [DLQI]) by the registry protocol were captured at the time of initiating Dupixent® treatment and are available for entry in the registry database
  • Able to understand and complete study-related questionnaires
  • Provide signed informed consent or parental/legally acceptable representative consent and/or patient assent where applicable

Exclusion Criteria:

  • Participants who have a contraindication to the drug according to the country-specific prescribing information label
  • Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other co-morbidities that can predictably prevent the participant patient from adequately completing the schedule of visits and assessments
  • Patients currently participating in any interventional clinical trial which modifies patient care
  • Prior use of Dupixent® within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03992417


Locations
Show Show 31 study locations
Sponsors and Collaborators
Sanofi
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT03992417    
Other Study ID Numbers: OBS15990
First Posted: June 20, 2019    Key Record Dates
Last Update Posted: May 9, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
 Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases